Pancreatic Cancer Research

ResearcherDalian University of TechnologyActive in the last 2 years

Xufeng Tao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4416-2234; OpenAlex author ID A5007466918, A5033189219. Sources: OpenAlex.

Their work

Papers
14 (first author 4, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
25
Papers, trials and grants by year

2020: 1 paper · 2021: 5 papers · 2022: 1 paper · 2023: 2 papers · 2024: 1 paper · 2025: 1 paper · 2026: 3 papers

Papers 14

  1. Lipid Nanoparticle-Based αHTRA1 mRNA Improves Pancreatic Ductal Adenocarcinoma Redox Microenvironment by Suppressing HTRA1/HIF-1 Signaling. First author DOI 10.1021/acs.bioconjchem.6c00013↗
  2. Peptides in the Diagnosis and Treatment of Pancreatic Cancer and Other Pancreatic Diseases from Basic Research to Clinical Translation. Last author DOI 10.2147/dddt.s610190↗
  3. Targeted drug delivery systems for pancreatic cancer therapy: advances, challenges, and future perspectives. First author DOI 10.3389/fimmu.2026.1785625↗
  4. Targeted mitochondrial therapy for pancreatic cancer. Co-author DOI 10.1016/j.tranon.2025.102340↗
  5. Carfilzomib relieves pancreatitis-initiated pancreatic ductal adenocarcinoma by inhibiting high-temperature requirement protein A1. First author DOI 10.1038/s41420-024-01806-w↗
  6. Metabolic reprogramming of immune cells in pancreatic cancer progression. Last author DOI 10.1016/j.biopha.2022.113992↗
  7. Advances in targeted therapy for pancreatic cancer. Co-author DOI 10.1016/j.biopha.2023.115717↗
  8. Berberine inhibits the proliferation of pancreatic cancer cells by targeting pancreatic cancer stem cells through regulating EMT signaling pathway Co-author DOI 10.32604/biocell.2022.020325↗
  9. Pancreatitis initiated pancreatic ductal adenocarcinoma: Pathophysiology explaining clinical evidence. Co-author DOI 10.1016/j.phrs.2021.105595↗
  10. MicroRNA-34a Alleviates Gemcitabine Resistance in Pancreatic Cancer by Repression of Cancer Stem Cell Renewal. Co-author DOI 10.1097/mpa.0000000000001920↗
  11. MicroRNAs in Pancreatic Cancer and Chemoresistance. Co-author DOI 10.1097/mpa.0000000000001934↗
  12. S100 Proteins in Pancreatic Cancer: Current Knowledge and Future Perspectives. Co-author DOI 10.3389/fonc.2021.711180↗
  13. Progress on the role of reactive oxygen species-mediated tumor microenvironment in pancreatic cancer. Co-author PMID 33903881↗
  14. T Lymphocytes: A Promising Immunotherapeutic Target for Pancreatitis and Pancreatic Cancer? First author DOI 10.3389/fonc.2020.00382↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Deshi Dong · 8 shared papers, 2021–2026 · strength 2.05
  2. Xiaonan Zhang · 3 shared papers, 2026 · strength 0.96
  3. Hong Xiang · 5 shared papers, 2020–2024 · strength 0.88
  4. Fangyue Guo · 4 shared papers, 2020–2026 · strength 0.84
  5. Gary Guishan Xiao · 5 shared papers, 2021–2022 · strength 0.82
  6. Guangshuo Gan · 2 shared papers, 2026 · strength 0.65
  7. Xinya Zhao · 2 shared papers, 2025–2026 · strength 0.64
  8. Dong Shang · 2 shared papers, 2021–2024 · strength 0.39
  9. Vay Liang W. Go · 2 shared papers, 2021 · strength 0.35
  10. Jing Liu · 1 shared paper, 2025 · strength 0.33
  11. Xu Yao · 1 shared paper, 2026 · strength 0.32
  12. Qi Zhou · 2 shared papers, 2020–2021 · strength 0.28
  13. Yue Pan · 2 shared papers, 2021 · strength 0.27
  14. Jianzhou Liu · 2 shared papers, 2021 · strength 0.27
  15. Ge Gao · 2 shared papers, 2021 · strength 0.27
  16. Yu Wu · 1 shared paper, 2024 · strength 0.24
  17. Lin Xing · 1 shared paper, 2023 · strength 0.18
  18. Mengmeng Liu · 1 shared paper, 2022 · strength 0.17
  19. Yu Wu · 1 shared paper, 2021 · strength 0.16
  20. Jing Huang · 1 shared paper, 2021 · strength 0.15
  21. Yue Pan · 1 shared paper, 2021 · strength 0.15
  22. Junchao Guo · 1 shared paper, 2021 · strength 0.15
  23. Dong Shang · 1 shared paper, 2020 · strength 0.13
  24. Shilin Xia · 1 shared paper, 2020 · strength 0.13
  25. Junchao Guo · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.